AUA 2022 | CORE1 trial: CG0070 plus pembrolizumab for BCG-unresponsive carcinoma-in-situ bladder cancer
Roger Li, MD, Moffitt Cancer Center, Tampa, FL, discusses the CORE1 trial (NCT04387461), a Phase II single-arm trial of the adenovirus oncolytic virus CG0070 plus pembrolizumab in patients with Bacillus Calmette-Guerin (BCG)-unresponsive carcinoma-in-situ bladder cancer. The primary endpoint was complete response rate (CR) at 12 months, determined via bladder biopsy. 20/22 patients achieved CR at 3 months and 6/8 patients achieved CR at 12 months. This interview took place at the American Urological Association annual congress 2022 in New Orleans and online.
Disclosures
Research support: Predicine; Decipher Biosciences. CG Oncology.
Clinical trial protocol committee – CG Oncology;
Scientific advisor/consultant – BMS, Ferring, Fergene, Arquer Diagnostics, Urogen Pharma, Lucence.
